Advertisement
CVS vs ELV
Which Stock Would AI Choose? CVS Health (CVS) vs. Elevance Health (ELV) Stock Comparison
Key Takeaways
- CVS Health operates a diversified model spanning pharmacy retail, pharmacy benefit management, and health insurance through Aetna, while Elevance Health focuses primarily on managed care and health insurance services.
- In recent weeks, CVS has consolidated gains after a strong multi-month rally, trading near $104–$107 with year-to-date returns exceeding 30% amid upcoming Q2 2026 earnings.
- ELV reported Q2 2026 results that beat expectations, raised full-year guidance, and saw its stock price around $375–$386, with 1-year returns near 36% despite a recent monthly pullback.
- Both stocks operate in the healthcare sector but face distinct pressures: CVS contends with reimbursement and legal risks, while ELV benefits from favorable benefit expense trends and share repurchase activity.
- Relative performance shows CVS with higher recent volatility and momentum, contrasted by ELV’s steadier earnings visibility and guidance upgrades in the past month.
- Market sentiment remains constructive for both, supported by sector tailwinds, though valuation metrics and upcoming catalysts differ in timing and impact.
Introduction
CVS Health and Elevance Health represent two prominent players in the U.S. healthcare industry, each with distinct business models that appeal to different investor profiles. This comparison examines their recent stock behavior, operational fundamentals, and positioning amid evolving market conditions. Institutional investors, sector-focused traders, and those seeking exposure to healthcare services may find the analysis relevant for assessing relative value, momentum, and risk profiles within the managed care and pharmacy benefit segments.
CVS Overview and Recent Performance
CVS Health Corporation delivers integrated healthcare solutions through its pharmacy services, retail pharmacies, and Aetna insurance operations. In recent market activity, the stock has consolidated near the $104–$107 range following a sharp rally earlier in the year, with year-to-date gains exceeding 30%. Positive factors include margin improvement in the health benefits segment and growth in high-demand therapeutic categories. Sentiment has been influenced by upcoming Q2 2026 earnings scheduled for August 5, alongside ongoing discussions around reimbursement pressures and legal matters. Trading volumes have remained elevated, reflecting institutional interest during this consolidation phase.
ELV Overview and Recent Performance
Elevance Health, Inc. provides managed care services, including health insurance plans and related benefits across multiple states. The company reported second-quarter 2026 results in mid-July that exceeded expectations, with operating revenue of $49.8 billion and adjusted diluted EPS of $7.45, prompting an upward revision to full-year guidance. In recent weeks, shares have traded near $375–$386, delivering approximately 36% returns over the trailing 12 months despite a modest pullback in the most recent month. Performance has been supported by disciplined expense management and active capital return programs, including share repurchases. Broader market activity reflects steady demand for its diversified portfolio of health plans.
Trending AI Robots
Tickeron maintains a curated selection of AI-powered trading bots designed to navigate thousands of tickers across varying market conditions. While the platform offers hundreds of such bots with diverse strategies, timeframes, and performance statistics, only those demonstrating the strongest alignment with prevailing trends and risk parameters earn placement in the Trending AI Robots section. Available bots exhibit a wide range of metrics, including varying win rates, drawdown profiles, and annualized returns that reflect their unique approaches to equity selection and position management. This dynamic curation helps users identify tools suited to current environments. Explore the full collection on the Trending AI Robots page for detailed statistics and strategy overviews.
Head-to-Head Comparison
CVS Health’s integrated model combines retail pharmacy scale with insurance capabilities, creating exposure to both consumer-facing and payer dynamics, whereas Elevance Health concentrates on insurance and care management, offering more direct leverage to medical loss ratios and enrollment trends. Recent momentum favors CVS in terms of multi-month price appreciation, while ELV has delivered clearer earnings beats and guidance lifts in the latest reporting cycle. Risk factors differ: CVS faces heightened scrutiny on pharmacy benefit management practices and potential litigation, while ELV contends with regulatory changes in Medicaid and Medicare Advantage. Sector exposure overlaps in healthcare services, yet CVS carries additional retail and distribution elements that can amplify cyclical sensitivity. Market sentiment reflects balanced optimism, with both names supported by long-term demographic drivers but differentiated by near-term catalysts and valuation multiples.
Tickeron AI Verdict
Based on observable trend consistency, recent earnings execution, and relative positioning, Tickeron’s AI models currently assign a modest probabilistic edge to ELV due to its timely guidance raise and steadier fundamental visibility in the latest period. CVS demonstrates stronger multi-month price momentum but carries additional near-term event risk ahead of its earnings release. Outcomes remain subject to evolving market data and sector developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CVS is a Buy and ELV is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CVS’s FA Score shows that 3 FA rating(s) are green whileELV’s FA Score has 2 green FA rating(s).
- CVS’s FA Score: 3 green, 2 red.
- ELV’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CVS’s TA Score shows that 3 TA indicator(s) are bullish while ELV’s TA Score has 4 bullish TA indicator(s).
- CVS’s TA Score: 3 bullish, 5 bearish.
- ELV’s TA Score: 4 bullish, 4 bearish.
Price Growth
CVS (@Managed Health Care) experienced а -3.07% price change this week, while ELV (@Managed Health Care) price change was -0.49% for the same time period.
The average weekly price growth across all stocks in the @Managed Health Care industry was -2.68%. For the same industry, the average monthly price growth was -9.13%, and the average quarterly price growth was +40.99%.
Reported Earning Dates
CVS is expected to report earnings on Aug 05, 2026.
ELV is expected to report earnings on Oct 21, 2026.
Industries' Descriptions
@Managed Health Care (-2.68% weekly)Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.
| CVS | ELV | CVS / ELV | |
| Capitalization | 133B | 81.5B | 163% |
| EBITDA | 11.1B | N/A | - |
| Gain YTD | 34.666 | 8.314 | 417% |
| P/E Ratio | 45.80 | 16.62 | 276% |
| Revenue | 408B | 201B | 203% |
| Total Cash | N/A | 36B | - |
| Total Debt | 78.3B | 31B | 253% |
CVS | ELV | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 86 | 83 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 63 | 94 | |
SMR RATING 1..100 | 88 | 98 | |
PRICE GROWTH RATING 1..100 | 5 | 50 | |
P/E GROWTH RATING 1..100 | 6 | 22 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CVS's Valuation (3) in the Drugstore Chains industry is in the same range as ELV (6) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
CVS's Profit vs Risk Rating (63) in the Drugstore Chains industry is in the same range as ELV (94) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
CVS's SMR Rating (88) in the Drugstore Chains industry is in the same range as ELV (98) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
CVS's Price Growth Rating (5) in the Drugstore Chains industry is somewhat better than the same rating for ELV (50) in the Managed Health Care industry. This means that CVS’s stock grew somewhat faster than ELV’s over the last 12 months.
CVS's P/E Growth Rating (6) in the Drugstore Chains industry is in the same range as ELV (22) in the Managed Health Care industry. This means that CVS’s stock grew similarly to ELV’s over the last 12 months.
| CVS | ELV | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 78% | N/A |
| Stochastic ODDS (%) | 4 days ago 63% | 4 days ago 62% |
| Momentum ODDS (%) | 4 days ago 60% | 4 days ago 62% |
| MACD ODDS (%) | 4 days ago 54% | 4 days ago 65% |
| TrendWeek ODDS (%) | 4 days ago 59% | 4 days ago 58% |
| TrendMonth ODDS (%) | 4 days ago 62% | 4 days ago 56% |
| Advances ODDS (%) | 14 days ago 67% | 7 days ago 56% |
| Declines ODDS (%) | 4 days ago 58% | 11 days ago 57% |
| BollingerBands ODDS (%) | 4 days ago 64% | 4 days ago 70% |
| Aroon ODDS (%) | 4 days ago 63% | N/A |
Advertisement
ELV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ELV has been loosely correlated with UNH. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if ELV jumps, then UNH could also see price increases.